RxDoctor Payments Data

Lance Braye, MD

Family Medicine · Greenwood, SCNPI 1215420195

Payments from drug & device makers

$676in general payments, 2019–2025

Across 22 payments — averaging $30.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$173
  • Inspire Medical Systems, Inc.$139
  • Lilly USA, LLC$99
  • Gilead$52
  • Xeris Pharmaceuticals, Inc.$46
  • AbbVie$38
  • plus $130 from 6 others

What the payments were for

  • Food & beverage$676100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$676 in reported general payments places this provider in the 55th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$1,445
Medicare patients
38
Services billed
83

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$41,280
TrulicityDulaglutide20$38,829
JardianceEmpagliflozin28$34,250
EliquisApixaban50$33,338
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$18,536
MyrbetriqMirabegron12$14,111
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$12,759
EntrestoSacubitril/Valsartan15$12,275
MounjaroTirzepatide12$12,145
JanuviaSitagliptin Phosphate13$10,219
Albuterol Sulfate HfaAlbuterol Sulfate68$2,470
Diclofenac Sodium65$1,573
Pravastatin Sodium83$1,390
Atorvastatin Calcium140$1,213
Duloxetine Hcl30$1,113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$99$50,97432 claims
Novo NordiskOzempic$173$41,28030 claims
Boehringer IngelheimJardiance$17$34,25028 claims
NovartisEntresto$23$12,27515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Greenwood

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →